亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

医学 安慰剂 胎龄 帕利珠单抗 呼吸道感染 儿科 随机对照试验 内科学 相对风险 毛细支气管炎 呼吸系统 置信区间 怀孕 替代医学 病理 生物 遗传学
作者
Katherine L. O’Brien,Aruna Chandran,Robert Weatherholtz,Hasan S. Jafri,M. Pamela Griffin,Terramika Bellamy,Eugene V. Millar,Kathryn M. Jensen,Brian Harris,Raymond Reid,Lawrence H. Moulton,Genevieve A. Losonsky,Ruth A. Karron,Mathuram Santosham
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:15 (12): 1398-1408 被引量:192
标识
DOI:10.1016/s1473-3099(15)00247-9
摘要

Background Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in children. We aimed to assess the safety and efficacy of an anti-RSV monoclonal antibody (motavizumab) in healthy term (≥36 weeks' gestational age) infants for the prevention of medically attended RSV acute lower respiratory tract infections. Methods This phase 3, double-blind, placebo-controlled, randomised trial enrolled healthy Native American infants aged 6 months or younger who were born at 36 weeks' gestational age in southwestern USA, on the Navajo Nation, the White Mountain Apache reservation, and the San Carlos Apache Indian reservation. Participants were randomly assigned (2:1) to receive either five monthly intramuscular doses of motavizumab (15 mg/kg) or placebo. They were followed up for 150 days after the first dose, and the primary endpoints were respiratory admission to hospital with a positive result for RSV by RT-PCR and death caused by RSV. Participants were followed up for medically attended wheezing until they reached age 3 years. Analysis was by intention to treat (ITT). This trial is registered with ClinicalTrials.gov, number NCT00121108. Findings During the autumn seasons (October to December) between 2004 and 2007, 2127 infants of the 2596 infants enrolled were randomly assigned to receive either motavizumab (1417) or placebo (710). After ITT analysis, motavizumab resulted in an 87% relative reduction (relative risk [RR] 0·13, 95% CI 0·08–0·21) in the proportion of infants admitted to hospital with RSV (21 [2%] of 1417 participants who received motavizumab; 80 [11%] of 710 participants who received placebo, p<0·0001). Serious adverse events were less common in particpants taking motavizumab (212 [15%]) than particpants on placebo (148 [21%]). Six deaths occurred in study participants (motavizumab, n=4 [0·3%]; placebo, n=2 [0·3%]); none were deemed to be related to the study product. Hypersensitivity events were more common in patients given motavizumab (208 [14·7%]) than in placebo recipients (87 [12·3%]; p=0·14). There was no effect on rates of medically attended wheezing in children aged 1–3 years (190 [14·9%] of participants randomly assigned to receive motavizumab vs 90 [14·0%] participants randomly assigned to receive placebo). Interpretation To our knowledge, this is the only trial of an anti-RSV antibody to prevent serious RSV disease in healthy term infants. Motavizumab significantly reduced the RSV-associated inpatient and outpatient burden and set a benchmark for the efficacy of RSV prevention strategies. The findings do not support a direct, generalisable, causal association between RSV lower respiratory tract infection and subsequent long-term wheezing in term infants. Funding MedImmune.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
舒心鞋垫完成签到,获得积分10
4秒前
华仔的应助被爱学习的doge采纳,获得10
12秒前
李爱国的应助被爱学习的doge采纳,获得50
12秒前
12秒前
赘婿的应助被爱学习的doge采纳,获得10
13秒前
小马甲的应助被爱学习的doge采纳,获得10
13秒前
13秒前
13秒前
Owen的应助被爱学习的doge采纳,获得10
13秒前
斯文败类的应助被爱学习的doge采纳,获得30
14秒前
华仔的应助被爱学习的doge采纳,获得10
14秒前
19秒前
20秒前
桐桐的应助被爱学习的doge采纳,获得10
21秒前
21秒前
21秒前
共享精神的应助被爱学习的doge采纳,获得10
21秒前
顾矜的应助被爱学习的doge采纳,获得10
21秒前
Owen的应助被爱学习的doge采纳,获得10
21秒前
molihuakai的应助被爱学习的doge采纳,获得10
21秒前
JamesPei的应助被爱学习的doge采纳,获得10
21秒前
英姑的应助被爱学习的doge采纳,获得10
21秒前
35秒前
Ccccn完成签到,获得积分10
40秒前
Voiceless发布了新的文献求助10
43秒前
44秒前
满意的平凡完成签到,获得积分10
49秒前
伶俐的秀发完成签到,获得积分10
50秒前
ChenYQ完成签到,获得积分10
1分钟前
苹果完成签到 ,获得积分10
1分钟前
殷勤的半凡完成签到,获得积分10
1分钟前
耍酷的手套完成签到,获得积分10
1分钟前
1分钟前
1分钟前
充电宝的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
orixero的应助被爱学习的doge采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918